Nogo-A Expression in Glial CNS Tumors
Authors:
- Tanja KuhlmannTKTanja Kuhlmann
- Angelika GutenbergAGAngelika Gutenberg
- Hans-Jürgen SchultenHSHans-Jürgen Schulten
- Werner PaulusWPWerner Paulus
- Veit RohdeVRVeit Rohde
- Wolfgang BruckWBWolfgang Bruck
- 1 October 2008
- journal article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 32 (10) , 1444-1453
Abstract
Gliomas are the most frequent primary brain tumors. In a minority of cases, the differentiation between astrocytomas and oligodendrogliomas based on morphologic characteristics alone can be difficult; though it is important, as patients with oligodendrogliomas follow a more favorable clinical course. Here we report on the immunohistochemical expression pattern of the oligodendrocytic marker Nogo-A in 113 central nervous system tumors including 28 oligodendrogliomas [15, World Health Organization (WHO) grade II; 13, grade WHO III], 50 astrocytomas [10, grade WHO II; 11, grade WHO III; 29 glioblastoma multiforme (GBM)], 11 ependymomas WHO grade II, 7 central neurocytomas, 2 dysembryoplastic neuroepithelial tumors (DNTs), 5 clear cell meningiomas, and 10 metastases to the brain. The oligodendrocytic marker Nogo-A was found to be strongly expressed in 71% of oligodendrogliomas, but in 0% of ependymomas WHO grade II, astrocytomas WHO grade II or III, DNTs, central neurocytomas, or clear cell meningiomas. In GBM, a subgroup of tumors (24%) showed strong expression of Nogo-A coincidently with Ki67 positivity but glial fibrillary acidic protein-negativity. However, neither in oligodendrogliomas nor GBM was a correlation between the loss of 1p19q and the extent of Nogo-A expression observed. Our findings indicate that Nogo-A is strongly expressed in the majority of oligodendrogliomas and might be a helpful marker to distinguish oligodendrogliomas from astrocytomas WHO grades II and III as well as ependymomas. They also support the hypothesis that GBM may be a heterogeneous group of tumors derived from different progenitor cells.Keywords
This publication has 35 references indexed in Scilit:
- Human Nogo-C overexpression induces HEK293 cell apoptosis via a mechanism that involves JNK-c-Jun pathwayBiochemical and Biophysical Research Communications, 2006
- Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402Journal of Clinical Oncology, 2006
- In vitro identification and functional characterization of glial precursor cells in human gliomasNeuropathology and Applied Neurobiology, 2006
- Oligodendroglial-specific Transcriptional Factor SOX10 is Ubiquitously Expressed in Human GliomasJournal of Neuro-Oncology, 2005
- Expression pattern of NOGO-A protein in the human nervous systemActa Neuropathologica, 2004
- Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cellsJournal of Neurosurgery, 2003
- Patterns of Nogo mRNA and Protein Expression in the Developing and Adult Rat and After CNS LesionsThe Journal of Neuroscience, 2002
- Astrocytes Give Rise to Oligodendrogliomas and Astrocytomas after Gene Transfer of Polyoma Virus Middle T Antigen in VivoThe American Journal of Pathology, 2000
- Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1Nature, 2000
- Identification of the Nogo inhibitor of axon regeneration as a Reticulon proteinNature, 2000